A Study of Juvenile Idiopathic Arthritis Patients Given Abatacept and the Number of Infections or Malignancies That Occur
Completed
- Conditions
- Juvenile Idiopathic Arthritis
- Registration Number
- NCT03769558
- Lead Sponsor
- Bristol-Myers Squibb
- Brief Summary
This study will determine the incidences of infections and malignancies among JIA patients treated with abatacept
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 264
Inclusion Criteria
- Two diagnoses of JIA (ICD-9 code 714.3x) within 90 days
- Age less than 18 years at the time of second of the two diagnoses
- Index date is the date of initiating treatment with abatacept
Exclusion Criteria
- Greater than or equal to 18 years of age
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Incidence of infections 110 months
- Secondary Outcome Measures
Name Time Method Incidence of malignancies 110 months
Trial Locations
- Locations (1)
Local Institution
🇺🇸Princeton, New Jersey, United States
Local Institution🇺🇸Princeton, New Jersey, United States